//
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed
The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories
INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction